Reolysin: Completed Phase II enrollment

Oncolytics Biotech said the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE